EUROLAB
usp-905-uniformity-of-dosage-units-affected-by-impurities
Impurity Profiling EMA Guideline on Genotoxic Impurities in PharmaceuticalsEMA Reflection Paper on Low Level ImpuritiesFDA Guidance: Microbial Impurities and Endotoxin LevelsFDA Guidance: Threshold of Toxicological Concern (TTC) for ImpuritiesFDA ICH M3(R2): Impurities in Safety StudiesFDA Q&A on Impurities in Generic Drug ApplicationsFDA Q&A: Managing Impurities in Complex APIsICH E14: QT Interval Evaluation and Impurity ImpactICH M7: Mutagenic Impurity Risk AssessmentICH Q10: Pharmaceutical Quality System for Impurity ManagementICH Q11: Impurity Control Strategy in Drug Substance DevelopmentICH Q12: Lifecycle Management of Impurity Control StrategyICH Q1E: Evaluation of Stability Data Related to Impurity FormationICH Q2(R1): Validation of Analytical Methods for Impurity TestingICH Q3A: Organic Impurity Profiling in Drug SubstancesICH Q3B: Impurity Testing in Finished Drug ProductsICH Q3C: Residual Solvent ProfilingICH Q3D: Elemental Impurity Risk AssessmentICH Q3F: Impurity Guidelines for Biotechnology ProductsICH Q4B: Harmonization of Analytical Procedures for Impurity TestingICH Q5C: Impurity Monitoring in Biotechnological ProductsICH Q6A: Specifications and Acceptance Criteria for ImpuritiesICH S3A: Impurities Arising from Degradation ProductsICH S6: Biotech Product Impurity ProfilingICH S7A: Safety Pharmacology Impurity EvaluationICH S9: Impurities in Oncology ProductsISO 10993-18: Chemical Characterization and Impurity AnalysisISO 17025: Accreditation for Impurity Testing LaboratoriesJP General Rule 2.60: Limit Test for ImpuritiesPh. Eur. 2.2.28: Gas Chromatography for Impurity DetectionPh. Eur. 2.2.38: Thin-Layer Chromatography for ImpuritiesPh. Eur. 2.2.46: Chromatographic Separation for Impurity AnalysisPh. Eur. 2.4.14: Determination of Inorganic ImpuritiesPh. Eur. 2.4.20: Limit Test for Heavy Metals in ImpuritiesPh. Eur. 2.4.24: Related Substances by HPLC in APIsPh. Eur. 2.4.29: Limit Test for Sulfated Ash ImpuritiesPh. Eur. 2.5.13: Oxidizing Impurity TestsPh. Eur. 2.9.40: Uniformity of Dosage Units and Related ImpuritiesPh. Eur. 5.10: Control of Impurities in Substances for Pharmaceutical UsePh. Eur. 5.4: Impurities in Radiopharmaceutical PreparationsUSP <1010>: Analytical Data Integrity in Impurity ReportingUSP <1031>: The Biocompatibility of Materials and ImpuritiesUSP <1051>: Cleaning Validation Limits and Residual ImpuritiesUSP <1058>: Analytical Instrument Qualification for Impurity StudiesUSP <1078>: Good Manufacturing Practices for Impurity ReductionUSP <1085>: Evaluation of Impurity Method PerformanceUSP <1086>: Impurities in Drug SubstancesUSP <1088>: Forced Degradation Studies for Impurity CharacterizationUSP <1091>: Impurity Isolation and Characterization TechniquesUSP <1099>: Acceptable Analytical Performance CriteriaUSP <1121>: Bulk Pharmaceutical Chemicals and Impurity HandlingUSP <1151>: Pharmaceutical Dosage Forms and Impurity ConsiderationUSP <1191>: Stability Testing of Compounded PreparationsUSP <1222>: Terminal Sterilization Impact on ImpuritiesUSP <1224>: Transfer of Impurity Test ProceduresUSP <1225>: Validation of Compendial Procedures for ImpuritiesUSP <1226>: Verification of Compendial Procedures for Impurity DetectionUSP <1231>: Water for Pharmaceutical Purposes and Impurity EffectsUSP <1232>: Water Activity and Impurity StabilityUSP <1241>: Capsules and Shell Impurity InteractionUSP <1251>: Weighing on Analytical Balances for Micro-ImpuritiesUSP <161>: Transdermal Delivery Systems and Impurity ControlUSP <197>: Spectrophotometric Identification of ImpuritiesUSP <233>: Elemental Impurities Profiling Using ICP-MSUSP <41>: Balances Used for Impurity Weight DeterminationUSP <466>: Identification and Quantification of DegradantsUSP <467>: Residual Solvent Testing in APIs and ExcipientsUSP <476>: Impurity Profiling for New Drug ApplicationsUSP <621>: Chromatography Conditions for Impurity IdentificationUSP <730>: Plasma Spectrochemistry for Impurity ProfilingUSP <791>: pH Determination Impact on Impurity SolubilityUSP <797>: Sterile Compounding and Impurity ControlUSP <800>: Hazardous Drug Handling Based on Impurity RiskUSP <851>: Spectrophotometry and Light Scattering for ImpuritiesUSP <853>: Atomic Absorption Spectroscopy for Trace ImpuritiesUSP <857>: UV-Vis Spectroscopy for Impurity QuantificationUSP <85>: Bacterial Endotoxin Limits Related to Impurity SafetyUSP <891>: Nuclear Magnetic Resonance (NMR) for Structural ElucidationUSP <905>: Content Uniformity Related to ImpuritiesUSP <941>: Characterization of Impurity Solubility and pKaWHO TRS 970 Annex 2: Impurity Control in Medicines

USP <905>: Uniformity of Dosage Units Affected by Impurities Laboratory Testing Service Provided by Eurolab

As a leading laboratory testing service provider, Eurolab understands the importance of ensuring the quality and consistency of pharmaceutical products. In this article, we will delve into the standards that govern USP <905>: Uniformity of Dosage Units Affected by Impurities testing.

International Standards

The United States Pharmacopeia (USP) is a non-profit organization that develops standards for pharmaceuticals in the United States and around the world. USP <905> is one such standard, which outlines the requirements for testing the uniformity of dosage units affected by impurities. The standard applies to various types of pharmaceutical products, including tablets, capsules, powders, and liquids.

ISO, ASTM, EN, TSE, and Other Standards

In addition to USP <905>, several other international standards organizations have developed guidelines for similar testing requirements:

  • International Organization for Standardization (ISO): ISO 9001:2015 outlines the quality management system requirements for organizations that develop pharmaceutical products.

  • American Society for Testing and Materials (ASTM): ASTM E 11-15 outlines the uniformity of dosage units affected by impurities testing requirements for various types of pharmaceutical products.

  • European Standard (EN): EN ISO 11133:2014 outlines the requirements for testing the uniformity of dosage units affected by impurities in pharmaceutical products.

    • National Standards

    In addition to international standards, national regulatory agencies also have established guidelines for USP <905> testing:

  • United States Food and Drug Administration (FDA): The FDA has adopted the USP <905> standard as a requirement for pharmaceutical manufacturers.

  • European Medicines Agency (EMA): The EMA has established guidelines for USP <905> testing in Europe.

    • Standard Development Organizations

    Several organizations are responsible for developing and maintaining standards related to USP <905>:

  • International Organization for Standardization (ISO)

  • American Society for Testing and Materials (ASTM)

  • European Committee for Standardization (CEN)

    • How Standards Evolve and Get Updated

    Standards evolve over time as new technologies, methods, or requirements emerge. The standard development process typically involves the following steps:

    1. Identification of needs: Organizations identify gaps in existing standards or develop new requirements.

    2. Drafting of proposals: Technical experts draft proposals outlining the new or updated requirements.

    3. Voting and approval: Members of the standard development organization vote on the proposals, and if approved, they become a new or revised standard.

    Standard Numbers and Scope

    Some relevant standard numbers related to USP <905> include:

  • USP <905>: Uniformity of Dosage Units Affected by Impurities

  • ISO 9001:2015: Quality Management System Requirements

  • ASTM E 11-15: Uniformity of Dosage Units Affected by Impurities Testing

    • Standard Compliance Requirements

    Compliance with USP <905> and other related standards is a requirement for pharmaceutical manufacturers:

  • Regulatory agencies enforce compliance with these standards to ensure product quality and safety.

  • Manufacturers must demonstrate compliance through testing, documentation, and record-keeping.

    • Consequences of Non-Compliance

    Non-compliance with USP <905> can have severe consequences for manufacturers:

  • Regulatory action: Agencies may issue warnings, fines, or even seize products that do not meet the standard.

  • Loss of reputation: Manufacturers risk damaging their reputation and losing customer trust if they fail to comply with standards.

    • The requirements outlined in USP <905> are essential for ensuring product quality and safety. Heres a breakdown of the standards scope, business and technical reasons for testing, consequences of non-compliance, and industries that require this testing:

    Why This Specific Test is Needed

    The Uniformity of Dosage Units Affected by Impurities test is critical in pharmaceutical manufacturing because it ensures that products are consistent and free from impurities. This is achieved through the following methods:

  • Sampling: Representative samples are taken from the production batch.

  • Analysis: The samples are analyzed using various techniques, such as high-performance liquid chromatography (HPLC) or gas chromatography (GC).

  • Data analysis: The results are evaluated to determine if the product meets the standard requirements.

    • Business and Technical Reasons for Conducting USP <905> Testing

    Pharmaceutical manufacturers must conduct USP <905> testing because:

  • Regulatory compliance: Manufacturers must comply with USP <905> to avoid regulatory action.

  • Product quality: The test ensures that products are consistent and free from impurities, which is essential for product safety and efficacy.

    • Consequences of Non-Compliance

    Non-compliance with USP <905> can have severe consequences, including:

  • Regulatory action

  • Loss of reputation

  • Monetary fines

    • Industries That Require This Testing

    USP <905> testing applies to various industries, including:

  • Pharmaceutical manufacturers

  • Biotechnology companies

  • Contract manufacturing organizations (CMOs)

    • The requirements outlined in USP <905> are essential for ensuring product quality and safety. Heres a breakdown of the standards scope, business and technical reasons for testing, consequences of non-compliance, and industries that require this testing:

    Why This Specific Test is Needed

    The Uniformity of Dosage Units Affected by Impurities test is critical in pharmaceutical manufacturing because it ensures that products are consistent and free from impurities. This is achieved through the following methods:

  • Sampling: Representative samples are taken from the production batch.

  • Analysis: The samples are analyzed using various techniques, such as high-performance liquid chromatography (HPLC) or gas chromatography (GC).

  • Data analysis: The results are evaluated to determine if the product meets the standard requirements.

    • Business and Technical Reasons for Conducting USP <905> Testing

    Pharmaceutical manufacturers must conduct USP <905> testing because:

  • Regulatory compliance: Manufacturers must comply with USP <905> to avoid regulatory action.

  • Product quality: The test ensures that products are consistent and free from impurities, which is essential for product safety and efficacy.

    • Consequences of Non-Compliance

    Non-compliance with USP <905> can have severe consequences, including:

  • Regulatory action

  • Loss of reputation

  • Monetary fines

    • Industries That Require This Testing

    USP <905> testing applies to various industries, including:

  • Pharmaceutical manufacturers

  • Biotechnology companies

  • Contract manufacturing organizations (CMOs)

    • Implementation of USP <905> involves several steps:

    1. Familiarize yourself with the standard: Understand the requirements outlined in USP <905>.

    2. Develop a testing plan: Create a plan outlining the sampling, analysis, and data evaluation procedures.

    3. Train personnel: Ensure that personnel conducting the test are trained and qualified to do so.

    4. Conduct testing: Perform the Uniformity of Dosage Units Affected by Impurities test according to the standard requirements.

    5. Document results: Record and document the results of the test.

    Compliance with Other Related Standards

    In addition to USP <905>, manufacturers must also comply with other related standards, such as:

  • ISO 9001:2015: Quality Management System Requirements

  • ASTM E 11-15: Uniformity of Dosage Units Affected by Impurities Testing

    • Benefits of Compliance

    Compliance with USP <905> and other related standards offers several benefits, including:

  • Regulatory compliance: Manufacturers avoid regulatory action.

  • Product quality: The test ensures that products are consistent and free from impurities.

  • Increased customer trust: Compliance demonstrates a commitment to product quality.

    • Challenges in Implementing USP <905>

    Implementing USP <905> can be challenging due to:

  • Lack of resources: Manufacturers may not have the necessary equipment, personnel, or training to conduct the test.

  • Regulatory complexity: The regulatory requirements outlined in USP <905> can be complex and difficult to understand.

    • Best Practices for Implementing USP <905>

    To overcome these challenges, manufacturers should:

    1. Develop a testing plan that outlines the sampling, analysis, and data evaluation procedures.

    2. Train personnel conducting the test to ensure they are qualified and knowledgeable about the standard requirements.

    3. Use validated equipment and methods to conduct the test.

    4. Document results accurately and keep records up-to-date.

    Implementation of USP <905> involves several steps:

    1. Familiarize yourself with the standard: Understand the requirements outlined in USP <905>.

    2. Develop a testing plan: Create a plan outlining the sampling, analysis, and data evaluation procedures.

    3. Train personnel: Ensure that personnel conducting the test are trained and qualified to do so.

    4. Conduct testing: Perform the Uniformity of Dosage Units Affected by Impurities test according to the standard requirements.

    5. Document results: Record and document the results of the test.

    Compliance with Other Related Standards

    In addition to USP <905>, manufacturers must also comply with other related standards, such as:

  • ISO 9001:2015: Quality Management System Requirements

  • ASTM E 11-15: Uniformity of Dosage Units Affected by Impurities Testing

    • Benefits of Compliance

    Compliance with USP <905> and other related standards offers several benefits, including:

  • Regulatory compliance: Manufacturers avoid regulatory action.

  • Product quality: The test ensures that products are consistent and free from impurities.

  • Increased customer trust: Compliance demonstrates a commitment to product quality.

    • Challenges in Implementing USP <905>

    Implementing USP <905> can be challenging due to:

  • Lack of resources: Manufacturers may not have the necessary equipment, personnel, or training to conduct the test.

  • Regulatory complexity: The regulatory requirements outlined in USP <905> can be complex and difficult to understand.

    • Best Practices for Implementing USP <905>

    To overcome these challenges, manufacturers should:

    1. Develop a testing plan that outlines the sampling, analysis, and data evaluation procedures.

    2. Train personnel conducting the test to ensure they are qualified and knowledgeable about the standard requirements.

    3. Use validated equipment and methods to conduct the test.

    4. Document results accurately and keep records up-to-date.

    Conclusion

    USP <905> is a critical standard for ensuring product quality in pharmaceutical manufacturing. Manufacturers must comply with this standard to avoid regulatory action, ensure product quality, and increase customer trust. By understanding the requirements outlined in USP <905>, developing a testing plan, training personnel, conducting the test accurately, and documenting results, manufacturers can successfully implement this standard.

    Need help or have a question?
    Contact us for prompt assistance and solutions.

    CONTACT US +902127020000

    Latest News

    View all

    Eurolab Successfully Renews ISO 17025 Accreditation

    Read More

    Expanded Cosmetic Safety Testing Portfolio Now Available at Eurolab

    Read More

    Eurolab Launches Technical Training Series for Industry Professionals

    Read More

    JOIN US
    Want to make a difference?

    Careers